ArticleESMO gastrointestinal oncology2025

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma.

M Tamba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.